[1] |
SHEN Chen, ZHOU Xian, LIU Jianping.
Database and Evaluation Methods for Chinese Herb-Drug Interactions
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 902-908.
|
[2] |
KE Xiuqin, HAI Xuewu.
433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
|
[3] |
XIE Rui, GENG Zihan, BAO Lei, ZHAO Ronghua, LI Shuran, SUN Qiyue, WANG Xinwei, ZHANG Jingsheng, CUI Xiaolan, GUO Shanshan, SUN Jing.
Research Progress in Pharmacological Actions, Mechanisms, Structural Modifications and Targeted Formulations of Ribavirin
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 950-955.
|
[4] |
ZHENG Sili, ZHANG Xiaoqing.
133 Cases of Adverse Drug Reactions in Female Patients
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 654-658.
|
[5] |
WANG Hao, MA Jinfu, MA Rui, LI Xiaogang, ZHAO Qiang, ZHANG Xian.
One Case of Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium for Injection
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 686-688.
|
[6] |
MEI Liping, BAI Fuchen, YU Jie, ZHANG Chunjie, WANG Yajun, AN Limei.
Determinants of Blood Drug Concentration / Dose Ratio of Antipsychotics
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 424-428.
|
[7] |
ZHONG Ling, ZENG Huiyan, YUAN Xin, WANG Yingyan.
Adverse Event Signals of Liraglutide and Semaglutide Based on the FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 305-312.
|
[8] |
ZOU Yuanlei, XIA Qingrong, LIANG Jun, HE Kongliang, MO Daming, WU Wenning.
Words of Warning and Preventive Measures in Labels of Antidepressants
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 329-333.
|
[9] |
ZHOU Kun, MA Liang, LI Zhaofeng, CAO Bing, GU Hongwei, LIU Qian.
Usage of Nerve-Calming Chinese Herbal Patent Medicines in a Mental Health Center
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 211-216.
|
[10] |
NIE Xiaolu, SUN Feng, YAN Aixia, PENG Xiaoxia, ZHAN Siyan.
Methodology for Constructing Benchmark Database of Adverse Drug Reactions Based on Multi-Source Information
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 10-15.
|
[11] |
ALATENG Hua, WANG Zhenxing, ZHANG Xiaomeng, SHI Wei, XI Chengwei, WANG Conghui, WANG Liqun, ZHANG Bing.
Mining and analysis of cardiac disorders risk signals based on adverse drug reaction monitoring data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 752-758.
|
[12] |
ZHAO Xuan, ZHENG Tingting, LI Xuemei, MAO Lu, GUO Jing, ZHANG Wei.
Adverse reaction reports of vancomycin in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 811-815.
|
[13] |
HJELMSTRÖM Peter, BOWRING Geoffrey, YUE Qun-Ying, NORÉN G. Niklas.
Methods for signal management using the global safety database VigiBase
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 836-840.
|
[14] |
SUN Xuelin, DU Jiao, TAN Qin, HU Xin, ZHANG Yatong, ZHENG Li.
Analysis of post-marketing adverse reactions of ametinib
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 683-686.
|
[15] |
LI Wenpeng, LIU Mingyu, CAO Ying, ZHOU Huziwei, WANG Shengfeng.
Supervision status and research progress of global abuse of opioids
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 513-518.
|